AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04060966 — intervention group
Intervention type: DEVICE
Intervention: fMRI
Description: Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
Study NCT02950376 — intervention group
Intervention type: OTHER
Intervention: DSM-5 +Virtual reality-based addiction assessment system
Description: The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
Study NCT02950376 — intervention group
Intervention type: OTHER
Intervention: Virtual reality-based addiction assessment system
Description: The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
Study NCT02950376 — intervention group
Intervention type: OTHER
Intervention: DSM-5 +Virtual reality-based addiction assessment system
Description: The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
Study NCT02986854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Description: One intramuscular injection of MenACWY at Day 1.
Study NCT02986854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Description: One intramuscular injection of MenACWY at Day 1.
Study NCT02470884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Fully Absorbable Scaffold
Description: Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
Study NCT03009084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
Study NCT03095456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Spiriva Handihaler®
Description: Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
Study NCT01655017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: adipose tissue biopsy (to evaluate inflammation and fibrosis)
Study NCT04025996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Assessments and Eye Assessments
Description: Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master
Study NCT00409617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg Every Other Week dosing
Study NCT00409617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
Study NCT02085187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine training and counselling
Description: Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required.
Study NCT01061658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine
Description: Lower dosage of vaccine
Study NCT01061658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01437540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
Study NCT00225095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells
Study NCT00225095 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyaluronan
Study NCT04563013 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
Study NCT04563013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
Study NCT00504374 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Symptoms questionnaire lasting about 5 to 10 minutes.
Study NCT02427503 — intervention group
Intervention type: PROCEDURE
Intervention: Asthma with NP and require surgery
Description: To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
Study NCT03369002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar
Description: Oral single dose 10 mg
Study NCT01437540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled formoterol fumarate 12 μg, twice per day
Study NCT01408342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab and Rituximab
Description: * Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21
Study NCT01707381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: Topical ophthalmic solution
Study NCT01707381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate
Description: Topical ophthalmic solution
Study NCT02935413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
Study NCT02935413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
Study NCT03843567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic characterisation training
Description: Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour.
Study NCT00375167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Workbook Training (psychoeducational training)
Description: The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
Study NCT03843567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic characterisation training
Description: Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour.
Study NCT04059575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (Performance Plus)
Description: PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
Study NCT00375167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT as usual
Description: Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
Study NCT02533895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV0113 DC-CIT
Description: Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
Study NCT04059575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping (Gold Tex)
Description: PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
Study NCT02533895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data evaluation
Description: For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc
Study NCT02533895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data evaluation
Description: For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc
Study NCT00093821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00093821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00093821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04569357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.
Study NCT04569357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1209
Description: QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
Study NCT04629846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
Study NCT04629846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT04629846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT00742755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective intervention
Description: Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
Study NCT01865383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microfinance and Health Leadership
Description: Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
Study NCT05030480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: renal functions
Description: urea, creatinine, GFR
Study NCT01581320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test group
Description: Once a month, administration of DP-R206 \& placebo for 16 weeks
Study NCT03256253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin up to 600 mg/day
Study NCT00769457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Access Arm
Description: Active OptiVol-System with CareAlert via CareLink
Study NCT01581320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference group
Description: Once a month, administration of Bonviva \& placebo for 16 weeks
Study NCT02222506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System
Description: KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
Study NCT02028390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scout takes visual and thermal images of external wounds
Description: All images are taken after the wound has acclimated.
Study NCT02028390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReview's visual perimeter trace of the external wound
Description: Trace is drawn by the study staff using the ImageReview software.
Study NCT01399866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 2 single weekly doses, 50 mg capsule
Study NCT01399866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02979145 — intervention group
Intervention type: OTHER
Intervention: No intervention involved
Study NCT01623739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a dental implant
Description: Type 1 implant placement Type 2 implant placement
Study NCT02793791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive ablation therapies
Description: Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
Study NCT02013245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC live vaccine
Description: Live-attenuated Mycobacterium tuberculosis vaccine
Study NCT02013245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available BCG live vaccine
Description: Live-attenuated Mycobacterium bovis vaccine
Study NCT01224080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adiana placement
Description: All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
Study NCT00661947 — intervention group
Intervention type: OTHER
Intervention: Dr Pepper sweetened with sucrose or high fructose corn syrup
Description: Comparison of different formulations of fructose.
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 1
Description: measurement in supine position
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Trendelenburg-position (ATB)
Description: measurement under ATB
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB in narcosis
Description: measurement under ATB in narcosis
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 1
Description: measurement in supine position in narcosis
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: measurement under passive leg raising
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume bolus substitution
Description: measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 2
Description: measurement in supine position
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: start capnoperitoneum
Description: measurement in supine position
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum
Description: measurement under ATB plus capnoperitoneum
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum plus volume bolus substitution
Description: measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB loss of capnoperitoneum
Description: measurement under ATB
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline
Description: measurement in supine position
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 2
Description: measurement in supine position
Study NCT03184285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the beginning
Description: measurement in the recovery unit